.Nature Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ state-of-the-art bosom cancer cells and also energetic or even stable mind metastases presented regular intracranial activity as well as systemic efficacy of T-DXd.